MARKET

QURE

QURE

Uniqure
NASDAQ
23.08
+0.77
+3.45%
Closed 19:27 01/07 EST
OPEN
22.21
PREV CLOSE
22.31
HIGH
24.43
LOW
22.11
VOLUME
1.70M
TURNOVER
0
52 WEEK HIGH
71.50
52 WEEK LOW
7.76
MARKET CAP
1.44B
P/E (TTM)
-5.2632
1D
5D
1M
3M
1Y
5Y
1D
uniQure Breaks Below 200-Day Moving Average - Notable for QURE
NASDAQ · 2d ago
QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP
Barchart · 2d ago
U.S. Chess Champion is Bullish on these 3 Stocks – In-Demand QURE, Unsexy AMZN and Reliable BRK.
TipRanks · 2d ago
Weekly Report: what happened at QURE last week (1229-0102)?
Weekly Report · 3d ago
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
PR Newswire · 12/30/2025 02:40
Weekly Report: what happened at QURE last week (1222-1226)?
Weekly Report · 12/29/2025 09:58
uniQure (QURE) Is Up 9.4% After FDA Deems AMT-130 Phase I/II Data Inadequate for Filing
Simply Wall St · 12/25/2025 13:24
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
PR Newswire · 12/23/2025 20:30
More
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers Uniqure NV stock information, including NASDAQ: QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.